Home>Topics>Stocks>Cadence Pharmaceuticals

Cadence Pharmaceuticals CADX

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. Mallinckrodt Reports Strong 4Q Results, but Shares Remain Overvalued


      Thu, 7 Aug 2014

      uncertainty surrounding Questcor. Revenue in the quarter was up 15% due to the inclusion of the recently acquired Cadence Pharmaceuticals business and its sole product, Ofirmev. Excluding the acquisition, sales grew 5%. Ofirmev results were

    2. Credit Market Outlook: Tight Spreads Will Keep a Lid on Returns


      Thu, 26 Jun 2014

      BBB from BBB+. Mallinckrodt MNK "> MNK will double its debt leverage to nearly 5 times in order to acquire Cadence Pharmaceuticals . While the deal gives Mallinckrodt a new platform to build out a hospital-focused pharmaceutical business

    3. Mallinckrodt Continues Its Acquisition Binge With Questcor Merger


      Mon, 7 Apr 2014

      billion merger with Questcor. The deal comes less than a month after Mallinckrodt closed its acquisition of Cadence Pharmaceuticals . The transaction will be funded approximately 35% with debt financing, and 65% with shares of Mallinckrodt

    4. Mallinckrodt's Acquisition of Cadence Pharmaceuticals Looks Like a Stretch


      Tue, 11 Feb 2014

      Mallinckrodt announced today that is acquiring Cadence Pharmaceuticals for $1.3 billion. The deal gives Mallinckrodt a new platform to build out a hospital-focused pharmaceutical business, but

    5. Cadence Pharma falls to life-low on disappointing results


      Fri, 4 May 2012

      (Reuters) - Cadence Pharmaceuticals Inc's shares fell to their life-low after the biopharmaceutical company reported a larger-than-expected first-quarter loss on costs related to the recall of its...

    6. Dropping Coverage of Cadence Pharmaceuticals


      Mon, 29 Aug 2011

      We are no longer providing equity research on Cadence Pharmaceuticals CADX . We provide broad coverage of more than 1,700 companies across more than 140 industries and adjust our coverage as necessary based on client demand and investor interest.

    7. 17 Highly Shorted Stocks Ready for a Squeeze


      Mon, 4 Apr 2011

      Kurtis Hemmerling submits: A high amount of short-selling may take place in a stock for a few reasons. One may be that analysts may have lowered thier rating or earnings forecasts for a stock. Margins may be sliding and the earning potential for the company is in serious doubt. Such fiscal problems

    8. Cadence's Fourth-Quarter Costs Beat Our Expectations


      Fri, 4 Mar 2011

      Cadence Pharmaceuticals CADX reported fourth-quarter results with costs coming in below our expectations. However, this did not have a material impact on

    9. New Morningstar Analyst Report - Cadence Pharmaceuticals , Inc.

      Stock Reports

      Wed, 23 Feb 2011

      provisions can favor executives over common shareholders. Cadence Pharmaceuticals in-licenses, develops, and markets drugs for the ..... regulations on pain medications could also harm sales. Cadence Pharmaceuticals has won Food and Drug Administration approval of its

    10. Approval for Cadence Pharma's Lead Drug


      Thu, 4 Nov 2010

      Cadence Pharmaceuticals CADX received Food and Drug Administration approval for lead drug candidate Ofirmev, an intravenous acetaminophen. At first glance

    « Prev123Next »
    Content Partners